MIRA Pharma awards CEO $242K STI, $915K transaction award, and 62,500 PSUs

MIRA PHARMACEUTICALS, INC.

CEO Erez Aminov receives $242,258 short-term incentive payout for 2025 performance; additional $80,753 contingent on Phase 1 study completion.
Transaction advisory award of $915,000 approved for negotiating SKNY acquisition; payable in cash, equity, or both at CEO's election.
62,500 performance share units issued and immediately vested upon achievement of first market capitalization milestone under LTI plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.